The aging effect of chemotherapy on cultured human mesenchymal stem cells

Experimental Hematology

Volumn 39, Issue 12, 2011, Pages 1171-1181

  Buttiglieri, Stefano ^a   Ruella, Marco ^a,b   Risso, Alessandra ^a   Spatola, Tiziana ^a   Silengo, Lorenzo ^a   Avvedimento, Enrico Vittorio ^c   Tarella, Corrado ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b MAURIZIANO HOSPITAL   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; DOXORUBICIN; ETOPOSIDE; TELOMERASE;

ADIPOSE TISSUE CELL; ADULT; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CELL AGING; CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL LYSATE; CELL PROLIFERATION; CLONOGENESIS; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DRUG EXPOSURE; ENZYME ACTIVATION; FLOW FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HYBRIDIZATION; IMMUNOPHENOTYPING; IN VITRO STUDY; MESENCHYMAL STEM CELL; PREDICTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SOUTHERN BLOTTING; TARGET CELL; TELOMERE; TELOMERE LENGTH; TELOMERE SHORTENING; THROMBOCYTE;

ADIPOCYTES; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BONE MARROW CELLS; CELL AGING; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELLS, CULTURED; DNA BREAKS, DOUBLE-STRANDED; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ETOPOSIDE; HUMANS; MESENCHYMAL STEM CELLS; NEOPLASM PROTEINS; OSTEOBLASTS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; TELOMERE; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEINS;

EID: 81155148297     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2011.08.009     Document Type: Article

References (54)

1. Hayflick L. The limited in vitro life time of human diploid cell strains. Exp Cell Res 1965, 37:614-636.
2. Yang Q. Cellular senescence, telomere recombination and maintenance. Cytogenet Genome Res 2008, 122:211-218.
3. Serrano M., Blasco M.A. Putting the stress on senescence. Curr Opin Cell Biol 2001, 13:748-753.
4. Lloyd A.C. Limits to lifespan. Nat Cell Biol 2002, 4:E25-E27.
5. Narita M., Nunez S., Heard E., et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003, 113:703-716.
6. Mimeault M., Batra S.K. Recent insights into the molecular mechanisms involved in aging and the malignant transformation of adult stem/progenitor cells and their therapeutic implications. Ageing Res Rev 2009, 8:94-112.
7. Harly C.B. Telomere loss: mitotic clock or genetic time bomb?. Mutat Res 1991, 265:271-282.
8. Vaziri H., Dragowska W., Allsopp R.C., et al. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci U S A 1994, 91:9857-9860.
9. Lansdorp P.M. Telomere length and proliferation potential of hematopoietic stem cells. J Cell Sci 1995, 108:1-6.
10. Blackburn E.H. Switching and signaling at the telomere. Cell 2001, 106:661-673.
11. Ben-Porath I., Weinberg R.A. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol 2005, 37:961-976.
12. Gewirtz D.A., Holt S.H., Elmore L.W. Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation. Biochem Pharmacol 2008, 76:947-957.
13. Duan J., Duan J., Zhang Z., Tong T. Irreversible cellular senescence induced by prolonged exposure to H2O2 involves DNA-damage-and-repair genes and telomere shortening. Int J Biochem Cell Biol 2005, 37:1407-1420.
14. Gorbunova V., Seluanov A., Pereira-Smith O.M. Expression of human telomerase (hTERT) does not prevent stress induced senescence in normal human fibroblasts but protects the cells from stress-induced apoptosis and necrosis. J Biol Chem 2002, 277:38540-38549.
15. Katakura Y., Nakata E., Miura T., Shirahata S. Transforming growth factor beta triggers two independent-senescence programs in cancer cells. Biochem Biophys Res Commun 1999, 255:110-115.
16. Yaswen P., Campisi J. Oncogene-induced senescence pathways weave an intricate tapestry. Cell 2007, 128:233-234.
17. Lee J.J., Nam C.E., Cho S.H., Park K.S., Chung I.J., Kim H.J. Telomere length shortening in non-Hodgkin's lymphoma patients undergoing chemotherapy. Ann Hematol 2003, 82:492-495.
18. Akiyama M., Asai O., Kuraishi Y., et al. Shortening of telomere in recipients of both autologous and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2000, 25:441-447.
19. Wynn R.F., Cross M.A., Hatton C., et al. Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet 1998, 351:178-181.
20. Seligman S.J. Telomere shortening in recipients of bone-marrow transplants. Lancet 1998, 351:1287-1288.
21. Schröder C.P., Wisman G.B., de Jong S., et al. Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer 2001, 84:1348-1353.
22. Ricca I., Compagno M., Ladetto M., et al. Marked telomere shortening in mobilized Peripheral Blood Progenitor Cells (PBPC) following two tightly-spaced high-dose chemotherapy courses with G-CSF. Leukemia 2005, 19:644-651.
23. Widmann T., Kneer H., Konig J., Hermann M., Pfreundschuh M. Sustained telomere erosion due to increased stem cell turnover during triple autologous hematopoietic stem cell transplantation. Exp Hematol 2008, 36:104-110.
24. Lansdorp P.M. Self-renewal of stem cells. Biol Blood Marrow Transplant 1997, 3:171-178.
25. Spangrude G.J., Heimfeld S., Weissman I.L. Purification and characterization of mouse hematopoietic stem cells. Science 1988, 241:58-62.
26. Prockop D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997, 276:71-74.
27. Pittenger M.F., Mackay A.M., Beck S.C., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
28. Gronthos S., Zannettino A.C., Hay S.J., et al. Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci 2003, 116:1827-1835.
29. Pountos I., Giannoudis P.V. Biology of mesenchymal stem cells. Injury 2005, 36:S8-S12.
30. Capelli C., Domenghini M., Borleri G., et al. Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. Bone Marrow Transplant 2007, 40:785-791.
31. Hultdin M., Grönlund E., Norrback K., Eriksson-Lindström E., Just T., Roos G. Telomere analysis by fluorescence in situ hybridization and flow cytometry. Nucleic Acids Res 1998, 26:3651-3656.
32. Sharpless N.E., DePinho R.A. How stem cells age and why this makes us grow old. Nature Rev Mol Cell Biol 2007, 8:703-713.
33. Rossi D.J., Jamieson C.H., Weissman I.L. Stems cells and the pathways to aging and cancer. Cell 2008, 132:681-696.
34. Calado R.T., Young N.S. Telomere diseases. N Engl J Med 2009, 361:2353-2365.
35. Verfaillie C.M. Hematopoietic stem cells for transplantation. Nat Immunol 2002, 3:314-317.
36. Jones R.J., Wagner J.E., Celano P., Zicha M.S., Sharkis S.J. Separation of pluripotent haematopoietic stem cells from spleen colony-forming cells. Nature 1990, 347:188-189.
37. Chamberlain G., Fox J., Ashton B., Middleton J. Mesenchymal stem cells: their phenotype, differentiation capacity, immunological fetures, and potential for homing. Stem Cells 2007, 25:2739-2749.
38. Shelton D.N., Chang E., Whittier P.S., Choi D., Funk W.D. Microarray analysis of replicative senescence. Curr Biol 1999, 9:939-945.
39. Ben-Porath I., Weinberg R.A. When cells get stressed: An integrative view of cellular senescence. J Clin Invest 2004, 113:8-13.
40. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88:593-602.
41. Elmore L.W., Rehder C.W., Di X., et al. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J Biol Chem 2002, 277:35509-35515.
42. Jones K.R., Elmore L.W., Jackson-Cook C., et al. p53-dependent accelerated senescence induced by ionizing radiation in breast tumour cells. Int J Radiat Biol 2005, 81:445-458.
43. Rocci A., Ricca I., Dellacasa C., et al. Long-term lymphoma survivors following high-dose chemotherapy and autograft: evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir. Exp Hematol 2007, 35:673-681.
44. Aubert G., Lansdorp P.M. Telomeres and aging. Physiol Rev 2008, 88:557-579.
45. Ju Z., Jiang H., Jaworski M., et al. Telomere dysfunction induces environmental alterations limiting hematopoietic stem cell function and engraftment. Nat Med 2007, 13:742-747.
46. Wahl G.M., Carr A.M. The evolution of diverse biological responses to DNA damage: Insights from yeast and p53. Nat Cell Biol 2001, 3:E277-E286.
47. Ross S.E., Hemati N., Longo K.A., et al. Inhibition of adipogenesis by Wnt signaling. Science 2000, 289:950-953.
48. Tchkonia T., Morbeck D.E., von Zglinicki T., et al. Fat tissue, aging, and cellular senescence. Aging Cell 2010, 9:667-684.
49. Sethe S., Scutt A., Stolzing A. Aging of mesenchymal stem cells. Ageing Res Rev 2006, 5:91-116.
50. Zhang X., Li J., Sejas D.P., Pang Q. The ATM/p53/p21 pathway influences cell fate decision between apoptosis and senescence in reoxygenated hematopoietic progenitor cells. J Biol Chem 2005, 280:19635-19640.
51. Rainey M.D., Charlton M.E., Stanton R.V., Kastan M.B. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res 2008, 68:7466-7474.
52. Alexander A., Cai S.L., Kim J., et al. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci U S A 2010, 107:4153-4158.
53. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003, 3:155-168.
54. Denchi E.L. Give me a break: How telomeres suppress the DNA damage response. DNA Repair 2009, 8:1118-1126.